LLY Eli Lilly and Company
Company Analysis
Latest News
Eli Lilly Expands into Ophthalmic Gene Therapy with $475M MeiraGTx Collaboration
Eli Lilly and Company announced a strategic licensing deal with MeiraGTx to develop gene therapies for eye diseases, marking a significant expansion into...
Eli Lilly Enters $1.2B Licensing Deal for RNAi Metabolic Disease Therapeutics
Eli Lilly and Company has entered into a significant research and licensing agreement with SanegeneBio to discover, develop, and commercialize RNA interference...
Eli Lilly's Stock Price Target Increased to $1,100 by BMO Capital
BMO Capital Markets has raised its price target for Eli Lilly to $1,100 from $930, maintaining an Outperform rating. This significant increase is attributed to...
Eli Lilly Stock Rises on Substantial Progress Announcement
On November 4, 2025, Eli Lilly and Company shares rose 1.13% to $906.69, continuing a strong multi-day rally. The price movement was driven by news that the...
Eli Lilly and Novo Nordisk Reportedly Nearing US Deal to Lower Obesity Drug Prices for Medicare Coverage
Eli Lilly and Novo Nordisk are reportedly nearing a deal with the White House to lower the prices of their popular obesity drugs in exchange for securing...
Eli Lilly Announces $3 Billion Investment in New Netherlands Manufacturing Facility
Eli Lilly and Company has announced plans to build a new $3 billion (€2.6 billion) manufacturing facility in Katwijk, the Netherlands. The site, located within...
Eli Lilly Beats Q3 Estimates and Raises Full-Year Guidance on Strong Weight-Loss Drug Sales
Eli Lilly and Company announced third-quarter financial results that significantly surpassed Wall Street expectations, driven by surging demand for its...
Eli Lilly Announces $1.2 Billion Puerto Rico Manufacturing Expansion
On October 29, 2025, Eli Lilly announced a planned investment of more than $1.2 billion to expand and modernize its Lilly del Caribe manufacturing site in...
Eli Lilly Partners with Walmart to Offer Zepbound with Direct-to-Consumer Pricing at Retail Pharmacies
Eli Lilly and Company has announced a collaboration with Walmart to make its weight-loss drug, Zepbound, available for pick-up at Walmart pharmacies nationwide...
Eli Lilly Announces Partnership with NVIDIA for Industry-Leading AI Supercomputer
On October 28, 2025, Eli Lilly announced a major collaboration with NVIDIA to build the industry's most powerful AI supercomputer, aiming to accelerate drug...
Eli Lilly CEO Reveals Billions of Oral Weight-Loss Pills Already Produced Ahead of FDA Submission
Eli Lilly's CEO, Dave Ricks, announced that the company has already manufactured billions of doses of its next-generation oral weight-loss pill, orforglipron,...
Eli Lilly's Omvoh Shows Early, Sustained Bowel Urgency Improvement in Ulcerative Colitis Patients
Eli Lilly and Company announced new positive data from its Phase 3b LUCENT-URGE study for Omvoh, a treatment for moderately to severely active ulcerative...
Eli Lilly Announces Acquisition of Adverum Biotechnologies
On October 24, 2025, Eli Lilly announced an agreement to acquire Adverum Biotechnologies, including its leading Ixo-vec gene therapy candidate. The deal...
Eli Lilly advances $5B U.S. manufacturing expansion amid tariff risks
On October 24, 2025, Eli Lilly's $5 billion investment in a new Virginia manufacturing facility was highlighted, marking the first of four planned U.S. sites....
Eli Lilly Acquires Verve Therapeutics, Entering Cardiovascular Gene-Editing Field
Eli Lilly and Company has announced its acquisition of Verve Therapeutics, a move that marks its entry into the field of gene-editing for cardiovascular...
Eli Lilly Entrusts $25 Billion Retirement Portfolio to Goldman Sachs
Eli Lilly and Co. has decided to transfer the management of its $25 billion U.S. and Puerto Rican retirement assets to Goldman Sachs. This move, reported on...
Eli Lilly Shares Decline Following Trump's Remarks on Weight-Loss Drug Pricing
Eli Lilly and Company (LLY) shares experienced a significant drop of over 4% in premarket trading on Friday, October 17, 2025. The decline followed comments...
Eli Lilly's Oral Weight-Loss Drug Orforglipron Succeeds in Late-Stage Diabetes Trials
Eli Lilly and Company (NYSE: LLY) announced on October 15, 2025, that its experimental oral GLP-1 drug, orforglipron, achieved its primary and key secondary...
Eli Lilly to Unveil Key Overall Survival Data for Verzenio at ESMO 2025
Eli Lilly and Company announced it will present new clinical data from its oncology portfolio at the European Society for Medical Oncology (ESMO) Annual...
Eli Lilly to Unveil Key Overall Survival Data for Breast Cancer Drug Verzenio at ESMO 2025
On October 13, 2025, Eli Lilly and Company announced it will present new clinical data from its oncology portfolio at the European Society for Medical Oncology...